Understanding the opportunities and challenges of immunotherapy is essential for industry, academic and healthcare leaders to drive innovation, foster collaboration and ultimately improve patient care.
The success of immunotherapy, which uses the immune system to help fight cancer by recognizing and attacking cancer cells, represents a groundbreaking shift in cancer treatment. The evolving immunotherapy landscape offers opportunities for a number of technologies:
- Novel immune checkpoint inhibitors able to penetrate the tumor microenvironment to activate an effective immune response.
- Adoptive cell therapy to isolate immune cells from a patient or donor, expanding and modifying them ex-vivo (outside the body), and then infusing them back into the patient to target and destroy cancer cells.
- Cancer vaccines, either personalized to an individual’s tumor-specific mutations (neoantigens), or ‘off-the-shelf’ vaccines, are designed to trigger a response to a common cancer antigen.
- Nanotechnology /nanomaterials, delivering anticancer agents directly to the tumor site, promises to enhance the specificity and efficacy of treatment whilst minimizing side effects.
One of the most exciting opportunities is the development of combination therapies. Through the combination of immunotherapy with other well-known treatments, such as chemotherapy, radiotherapy or other targeted therapies, researchers are undertaking pioneering science to further enhance their effectiveness and overcome the resistance mechanisms that cancer cells often develop.
Whilst immunotherapy approaches have led to significant improvements in patient outcomes, challenges remain.
- Firstly, not all patients will respond to immunotherapy – every patient is different, with significant genetic and phenotypic variations. These variations make it challenging to predict which patients will benefit from a given treatment and which are likely to suffer from drug resistance.
- Management of side effects is a priority; balancing the efficacy of immunotherapy with patient safety. Side effects can sometimes be managed with corticosteroids or other immunosuppressive therapies, but there is a risk of long-term damage and / or other complications.
- Solid tumors often have a dense, immunosuppressive microenvironment that inhibits immune cell infiltration, and may have lower levels of neoantigens that the immune system can recognize, making them less susceptible to immune-mediated destruction.
Turning challenges into opportunities
Immunotherapy is one of the most promising areas in modern medicine. It holds the potential to advance personalized or precision medicine, where treatments are tailored to the specific genetic and molecular profiles of each patient’s disease. Combination approaches can maximize efficacy whilst minimizing the probability of resistance.
The roll-out of new biomarker strategies, including the use of liquid biopsies, will allow researchers to gather extensive, non-invasive data about a patient’s tumor. Identifying biomarkers and genetic mutations linked to responsiveness can help clinicians choose the most effective immunotherapies to increase response rates, prevent resistance, and predict toxicity.
As novel immunotherapies progress through development, their ability to extend the healthspan for patients is becoming increasingly clear.
Sources
